Effect of a combination of donepezil tablets and butylphthalide soft capsules on neurological function in dementia patients, and its effect on serum inflammatory factors
Purpose: To determine the effect of combined use of donepezil tablets and butylphthalide soft capsules in the treatment of patients with vascular dementia, and its effect on serum inflammatory factor levels and neurological functional recovery of patients.
Methods: 120 patients with vascular dementia were selected and assigned to group A (n = 60) and group B (n = 60). All patients were treated with donepezil tablets, while patients in group A were, in addition, treated with butylphthalide soft capsules. Mini mental state examination (MMSE) scores, clinical dementia rating scale (CDRS) scores, activities of daily living (ADL) scores, incidence of adverse reactions, serum inflammatory factor levels and neurological functional recovery were determined.
Results: There was significantly higher MMSE score in group A than in B, while CDRS score was lower in group A. The ADL scores and inflammatory factor levels were lower in group A than in B (p < 0.001), while neurological functional recovery was markedly better in A (p < 0.001). Incidents of unwanted events were comparable in groups A and B, and there were no serious complications in the patients.
Conclusion: The combination therapy of donepezil tablets and butylphthalide soft capsules reduces inflammatory factor levels and improved cognitive level and quality of life of patients with vascular dementia. It also produces good neurological functional recovery and low incidence of adverse reactions. Therefore, this treatment strategy has potentials for the management of vascular dementia.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.